ArticleBJC reports2023

Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial.

Mark Beresford et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.